Sector
PharmaceuticalsOpen
₹515Prev. Close
₹516Turnover(Lac.)
₹151.93Day's High
₹516.75Day's Low
₹514.7552 Week's High
₹052 Week's Low
₹0Book Value
₹-203.57Face Value
₹10Mkt Cap (₹ Cr.)
370.8P/E
0EPS
0Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 6.92 | 7.2 | 7.2 | 7.2 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -153.78 | -131.12 | -123.13 | -103.34 |
Net Worth | -146.86 | -123.92 | -115.93 | -96.14 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2017 | Mar-2016 | Mar-2015 | Mar-2014 |
|---|---|---|---|---|
Revenue | 135.38 | 118.99 | 115.98 | 119.96 |
yoy growth (%) | 13.77 | 2.59 | -3.32 | 11.38 |
Raw materials | -46.44 | -40.62 | -41.17 | -41.5 |
As % of sales | 34.3 | 34.14 | 35.5 | 34.59 |
Employee costs | -24.56 | -22.44 | -17.67 | -15.88 |
| Y/e 31 Mar( In .Cr) | Mar-2017 | Mar-2016 | Mar-2015 | Mar-2014 |
|---|---|---|---|---|
Profit before tax | -13.82 | -23.77 | 20.88 | 30.06 |
Depreciation | -16.3 | -16.12 | -4.6 | -3.44 |
Tax paid | 0 | 5.23 | -3.87 | -10.55 |
Working capital | 6.71 | 0.76 | -24.6 | 19.6 |
Other operating items |
| Y/e 31 Mar | Mar-2017 | Mar-2016 | Mar-2015 | Mar-2014 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 13.77 | 2.59 | -3.32 | 11.38 |
Op profit growth | 125.32 | -66.95 | -25.82 | 42.48 |
EBIT growth | -148.19 | -133.47 | -32 | 46.22 |
Net profit growth | -25.41 | -208.91 | -12.75 | 51.55 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.35 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493.2 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,483.15 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.4 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,167.95 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Director
SHIV CHARAN LAL GUPTA
Director
ARUN KUMAR GUPTA
Director
SUNINDER SINGH ARORA
Managing Director
INDRANIL MUKHERJEE
Director
ANDREAS WALDE
Additional Director
CHRISTOPH MUELLER
Company Secretary
RANJAN KUMAR SAHU
201-205 2nd Flr of ND Mall-1,
Plot 2-4 Netaji Subhash Place,
Delhi - 110034
Tel: 91-11-42344234
Website: http://www.ahlconindia.com
Email: ranjan.sahu@ahlconindia.com
T-34 2nd Floor,
Okhla Industrial Are, Phase II,
New Delhi - 110020
Tel: 91-011-26387281/83
Website: www.masserv.com
Email: info@massere.com
Summary
Earlier known as Gujarat Inject, the company was incorporated on 20 Jan.92. It has been promoted by Ahluwalia Contracts and Bikramjit Ahluwalia.It manufactures and markets IV fluids. Intravenous fluid...
Read More
Reports by Ahlcon Parenterals India Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.